In November 2026, Nako Nakatsuka and her clever team at the École Polytechnique Fédérale de Lausanne (EPFL) published a landmark study in Nature Chemistry detailing a novel small-molecule sensing method where paired synthetic DNA strands recognize molecular shape rather than sequence. They engineered this architecture specifically because traditional diagnostics have spent decades fumbling with minuscule molecules that refuse to play by standard rules.
Let's look at the reigning champions of diagnostics: the sandwich assay. You encounter them every time you take an at-home COVID test or use a pregnancy strip. These legacy platforms demand massive target proteins with plenty of physical surface area so two separate detector antibodies can latch onto tiny gold particles and flash a dark-red line. It works like a charm, provided your target molecule is large enough to handle a double-team.
Enter the low-molecular-weight analyte, nature's tiny biochemical prankster. Testosterone and serotonin completely lack the spatial surface area required to accommodate multiple simultaneous binding sites. Traditional assays throw their hands up in defeat here. But Nakatsuka’s Laboratory of Chemical Nanotechnology (CHEMINA) refused to accept that physical roadblock, deploying short, synthetic DNA aptamers to build a cooperative system where a single primary aptamer directly snares the target.
Skeptics always point out that older single-aptamer sensors hit a severe signal readout bottleneck, usually demanding expensive instrumentation just to catch a fluorescent hiccup. The EPFL crew bypassed that entire headache. They introduced a secondary aptamer programmed to recognize the distinct spatial conformation of the primary aptamer only after it binds, rendering complex auxiliary hardware entirely obsolete.
Have thoughts on this article?
Send your feedback. Spotted a factual error or typo? Use this form to let us know. We use your feedback to improve our reporting. Thank you!
